FDA
-
-
-
-
-
-
-
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
-
-
-
-
-
-
-
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
-
-
-
-
-
-
-
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
-
-
-
-
-
-
-
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Y-mAbs to Participate in Upcoming Investor Conferences in October
-
-
-
-
-
-
-
Y-mAbs Therapeutics (YMAB) Appoints Peter Pfreundschuh as CEO
-
-
-
-
-
-
-
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

